InfanDx AG wins new Investor and prepares for Round B Financing

Bonn, March 1st, 2017

InfanDx welcomes its new Investor Arnika Beteiligungen GmbH (Poing, near Munich) and thus enjoys significant tailwind in its approach to its next financing round coming at the second half of 2017. A “sizeable 6-digit sum” will help to more comfortably prepare and structure the projected development.

“We deeply appreciate the high level of trust while this advance investment helps to position ourselves optimally for the financing round in autumn 2017” states Ron Meyer, InfanDx’ CEO. Particularly the fact that both anchor investors of InfanDx, the Arnika Beteiligungen GmbH and the LSI Pre-Seed- Fonds GmbH declared readiness to co-invest in the upcoming round is seen as a strong signal to the investment community. „The strong combination of clear product focus with measurable benefit to healthcare and the high ethical impact for our youngest patients is exceptionally intriguing for us” explains Arnika CEO, Dr. Wolfgang Schwandner.

InfanDx currently benefits from an incubation program at Life Science Inkubator, Bonn (LSI) with support of the state North Rhine-Westphalia. This R&D phase is financed with more than 2 Mio. € and enables the project InfanDx to conduct two clinical research studies and significantly propel its development of a miniaturized test system.

This test, as first of its kind, will allow the early and reliable diagnosis of oxygen deficit during birth (perinatal asphyxia) and subsequent brain damage. It will fill a critical gap to enable the existing therapeutic approaches to reach early enough and help many affected children who are today overlooked and doomed to life long disability. Worldwide and each year >1 mio. babies suffer from NE, which makes it within the delivery period the largest single cause for life long morbidity. The biomarkers developed by the InfanDx-project will be the first diagnostic tool to reliably identify the babies in need early enough within the therapeutic time-window.

Download article as PDF:
English and German

Previous press releases:

InfanDx AG and LSI, Bonn, announce start of first clinical study (05/17/2016)

Each newborn baby deserves the best start into the future: Life Science Inkubator, Bonn/Germany, takes on the InfanDx-project to identify oxygen deficiency in newborn infant (01/22/2015)